• Policy
• Advance reservations for SKYCovione will begin on the 1st
• by Kim, Jung-Ju Sep 2, 2022 06:02am

• Company
• Trelegy Ellipta lands in Big 5 tertiary hospitals in Korea
• by Eo, Yun-Ho Sep 1, 2022 05:56am

• Policy
• MFDS sets next year's budget at ₩669.4 billion
• by Lee, Hye-Kyung Sep 1, 2022 05:56am

• Company
• Imported shingles vaccine that has been suspended & delayed
• by Sep 1, 2022 05:56am

• Policy
• Coverage of 19 new drug items will be reinforced this year
• by Kim, Jung-Ju Aug 31, 2022 05:40am

• Opinion
• [Reporter’s View] Novartis's restructuring path similar
• by Eo, Yun-Ho Aug 31, 2022 05:40am

• Product
• Change of insurance code for Tylenol ER 650mg
• by Kim JiEun Aug 31, 2022 05:40am

• Opinion
• [Reporter's view] Reflecting opinions on cold medicine
• by Lee, Hye-Kyung Aug 31, 2022 05:39am

• Policy
• Reevaluation of Amosartan plus & Twotops Plus
• by Lee, Tak-Sun Aug 30, 2022 05:55am

• Policy
• Lorviqua reimb at ₩52,819, Emgality at ₩295,250
• by Kim, Jung-Ju Aug 30, 2022 05:55am